Presentation on Proteasome Gene Regulation Set for Feb. 6 at UNLV

Feb. 2, 2015

Ray Deshaies, a Howard Hughes Medical Institute researcher and a biology professor at the California Institute of Technology, will discuss "The Basic Science and Clinical Significance of Proteasome Gene Regulation" Feb. 6 at 1 p.m. in UNLV’s White Hall Auditorium.

Deshaies’ pioneering research into regulated protein degradation eventually led to the development of carfilzomib, which has been approved by the FDA for the treatment of multiple myeloma.

He is a co-founder of biotech company Proteolix, which was acquired by Onyx Pharmaceuticals in 2009 for $851 million. More recently, he served as co-founder of Cleave Biosciences.

Deshaies, who was elected as a member of the American Academy of Arts and Sciences in 2011, was motivated to study cancer after the loss of a close family member. At his lecture, and will discuss how basic research can ultimately lead to a cancer therapy.

For more information, contact UNLV chemistry professor Gary Kleiger at gary.kleiger@unlv.edu or 702-895-3585.